Video
10 December 2025 - by Katherine M. Holcomb, Massey S. J. Whorley, James Cooper, Madeleine Feller
Gain timely insights into the upcoming Medicare Part D Maximum Fair Prices (MFP) for 2026 and 2027. Explore how these changes will impact coverage, access, and the competitive landscape for generics and biosimilars. Plus, discover the transformative power of anti-obesity demonstration models and what they mean for the future of healthcare.
Article
08 September 2025 - by Madeleine Feller, Rachel W. Madden, Katherine M. Holcomb
We offer updated insights into the individual Part D and Employer Group Waiver Plan markets, including substantial increases in drug costs, particularly among specialty drugs used by the NLI population.
Article
30 July 2025 - by Katherine M. Holcomb, Jake K. Klaisner, Philip Nelson, Ivanna Ulin
340B disproportionate share hospitals consistently have higher drug costs across commercial and Medicare plans, according to our latest study on this population.
Video
04 June 2025 - by Katherine M. Holcomb, Tyler Engel, Chris Page, Matthew Hayes
Explore the transformative impact of the Inflation Reduction Act and other government policies on the life sciences industry in 2025 and beyond.
Article
09 May 2025 - by Michelle (Klein) Robb, Katherine M. Holcomb, Ivanna Ulin
We review the impact of the Inflation Reduction Act on Medicare Part B provider payment and patient access, and estimate potential changes from a new bill.
Article
15 April 2025 - by Madeleine Feller, Rachel W. Madden, Katherine M. Holcomb
In our latest trend report on Medicare Part D, we present a more detailed review of utilization and cost patterns in the individual market through year-end 2024.
Article
07 February 2025 - by Dan Simenc, Jake K. Klaisner, Katherine M. Holcomb
We provide some insights on Medicare price negotiation's year-two selection, which expands to new therapeutic areas.
Article
03 February 2025 - by Madeleine Feller, Rachel W. Madden, Katherine M. Holcomb
We look at the top-line gross cost trends in Medicare Part D, focusing on factors that stakeholders should consider as they review 2024 prescription drug data.
Video
05 September 2024 - by Katherine M. Holcomb, Andrew L. Naugle
How will the Inflation Reduction Act raise health plan costs—and how will plans, beneficiaries, and manufacturers respond?
Article
05 September 2024 - by Katherine M. Holcomb, Madeleine Feller, Jake K. Klaisner, Jennifer Carioto, Gabriela Dieguez
We explore the implications of the 2026 maximum fair prices within Medicare price negotiation, part of a paradigm shift in Part D access and cost.